These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 9591913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H.
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [Abstract] [Full Text] [Related]

  • 3. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review.
    Hunt N, Stern TA.
    Psychosomatics; 1995 Dec; 36(6):541-9. PubMed ID: 7501784
    [Abstract] [Full Text] [Related]

  • 4. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H.
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Continuous infusion of haloperidol in agitated, critically ill patients.
    Stern TA.
    Crit Care Med; 1994 Mar; 22(3):378-9. PubMed ID: 8124985
    [No Abstract] [Full Text] [Related]

  • 8. Haloperidol-induced torsade de pointes.
    O'Brien JM, Rockwood RP, Suh KI.
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [Abstract] [Full Text] [Related]

  • 9. Torsade de pointes and low-dose oral haloperidol.
    Jackson T, Ditmanson L, Phibbs B.
    Arch Intern Med; 1997 Sep 22; 157(17):2013-5. PubMed ID: 9308514
    [Abstract] [Full Text] [Related]

  • 10. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
    Hassaballa HA, Balk RA.
    Expert Opin Drug Saf; 2003 Nov 22; 2(6):543-7. PubMed ID: 14585064
    [Abstract] [Full Text] [Related]

  • 11. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
    Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP.
    Drug Saf; 2012 Jul 01; 35(7):547-53. PubMed ID: 22702639
    [Abstract] [Full Text] [Related]

  • 12. A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
    Muzyk AJ, Rivelli SK, Jiang W, Heinz H, Rayfield A, Gagliardi JP.
    Drug Saf; 2012 Sep 01; 35(9):725-31. PubMed ID: 22876752
    [Abstract] [Full Text] [Related]

  • 13. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.
    Di Salvo TG, O'Gara PT.
    Clin Cardiol; 1995 May 01; 18(5):285-90. PubMed ID: 7628136
    [Abstract] [Full Text] [Related]

  • 14. Torsade de pointes associated with the administration of intravenous haloperidol.
    Hassaballa HA, Balk RA.
    Am J Ther; 2003 May 01; 10(1):58-60. PubMed ID: 12522522
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
    Fongemie JM, Al-Qadheeb NS, Estes NA, Roberts RJ, Temtanakitpaisan Y, Ruthazer R, Devlin JW.
    Pharmacotherapy; 2013 Jun 01; 33(6):589-97. PubMed ID: 23529904
    [Abstract] [Full Text] [Related]

  • 20. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
    Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V.
    Int J Clin Pharm; 2016 Apr 01; 38(2):310-20. PubMed ID: 26749342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.